Year two assessment of fenofibric acid and moderate-dose statin combination: A phase 3, open-label, extension study

Clinical Drug Investigation

Volumn 30, Issue 1, 2010, Pages 51-61

  Kipnes, Mark S ^a   Roth, Eli M ^b   Rhyne, James M ^c   Setze, Carolyn M ^d   Lele, Aditya ^d   Kelly, Maureen T ^d   Sleep, Darryl J ^d   Stolzenbach, James C ^d  

^a Cetero Research   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Lipid Center   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG OVERDOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROCETOFEN; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 72049124300     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11319800-000000000-00000     Document Type: Article

References (21)

1. Assmann G, Schulte H, Von Eckardstein A, et al. Highdensity lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 Jul; 124 Suppl.: S11-20
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996 Apr; 3 (2): 213-219
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-3421
4. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 Jan 30; 115 (4): 450-458
5. Minino AM, Heron MP, Murphy SL, et al. Deaths: final data for 2004. Natl Vital Stat Rep 2007; 55,19.
6. Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007 Mar; 23 (3): 553-563
7. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008 Nov 17; 102 (10 Suppl.): 1K-34K
8. Kiortisis DN, Millionis H, Bairaktari E, et al. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 2000 Dec; 56 (9-10): 631-635
9. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002 Jul; 25 (7): 1198-1202
10. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009; 103: 515-522
11. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). AmJ Cardiol 2005 Feb 15; 95 (4): 462-468
12. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009 May; 204 (1): 208-215
13. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009 Jan; 157 (1): 195-203
14. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003 Apr 15; 91 (8): 956-960
15. Jones PH, Bays HE,Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins. Clin Drug Invest 2008; 28 (10): 625-634
16. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008; 2: 426-435
17. American Heart Association. An eating plan for healthy Americans: our American Heart Association diet. AHA Publication No. 50-1481A. 2004
18. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006 Jan; 5 (1): 145-156
19. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 Nov 26; 366 (9500): 1849-1861
20. Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week, randomized, controlled studies. J Clin Lipidol 2009 April; 3 (2): 125-137
21. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 Jan; 32Suppl. 1: S13-61